US Stock MarketDetailed Quotes
PEPG PepGen
- 6.730
- +0.760+12.73%
Trading Dec 3 10:52 ET
219.37MMarket Cap-2258P/E (TTM)
6.850High6.100Low113.12KVolume6.430Open5.970Pre Close735.21KTurnover0.73%Turnover RatioLossP/E (Static)32.60MShares19.29852wk High1.60P/B104.21MFloat Cap4.00052wk Low--Dividend TTM15.48MShs Float20.000Historical High--Div YieldTTM12.56%Amplitude3.720Historical Low6.499Avg Price1Lot Size
About PepGen Company
PepGen Inc. develops oligonucleotide therapies. It is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics with the goal of transforming the treatment of severe neuromuscular and neurologic diseases. The company was founded in March 26, 2018 and is headquartered in Boston, MA.
Company Profile
SymbolPEPG
Company NamePepGen
Listing DateMay 6, 2022
Issue Price12.00
Founded2018
CEOMr. James McArthur, PhD
MarketNASDAQ
Employees64
Fiscal Year Ends12-31
Address321 Harrison Avenue,8th Floor
CityBoston
ProvinceMassachusetts
CountryUnited States of America
Zip Code02118
Phone1-781-797-0979
Websitehttp://pepgen.com
Company Executives
- Name
- Position
- Salary
- James McArthur, PhD
- President, Chief Executive Officer and Director
- 3.43M
- Noel Donnelly, M.B.A.
- Chief Financial Officer and Principal Accounting Officer
- 1.97M
- Dr. Niels Svenstrup, PhD
- Senior Vice President, Chemistry, Manufacturing and Control
- --
- Dr. Michelle L. Mellion, M.D.
- Senior Vice President, Clinical Development
- 1.41M
- Laurie B. Keating, J.D.
- Chairman of the Board
- 154.82K
- Dr. Howard Mayer, M.D.
- Independent Director
- 64.16K
- Habib Joseph Dable
- Independent Director
- 90.24K
- Heidi Henson, C.P.A.
- Independent Director
- 123.32K
- Mary Beth DeLena, J.D.
- General Counsel and Secretary
- --
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
